Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Kevin R. Murphy(Boys Town National Research Hospital), Mario Castro(National Institute for Health Research), John M. Fahrenholz, Joshua Jacobs(California Allergy and Asthma Medical Group), Leif Bjermer(Lund University), Yael Shalit(Teva Pharmaceuticals (Israel)), Margaret Garin(Teva Pharmaceuticals (Hungary)), James Zangrilli(Teva Pharmaceuticals (United States))
The Journal of Allergy and Clinical Immunology In Practice
November 1, 2017
Cited by 146
Related Papers
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
|New England Journal of Medicine|2018|1.9k
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
|CHEST Journal|2016|426
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329